Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)

BACKGROUND: High‐dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer (LAHNSCC) patients. As some patients are unable to tolerate Cis, this study compares the toxicity and efficacy of weekly cisplatin‐paclitaxel...

Descripción completa

Detalles Bibliográficos
Autores principales: Furqan, Muhammad, Snyders, Travis P., Saqlain, Mohammed U., Mott, Sarah L., Laux, Douglas, Snow, Anthony, Anderson, Carryn M., Watkins, John M., Clamon, Gerald H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558467/
https://www.ncbi.nlm.nih.gov/pubmed/30968604
http://dx.doi.org/10.1002/cam4.2139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558467/
https://www.ncbi.nlm.nih.gov/pubmed/30968604
http://dx.doi.org/10.1002/cam4.2139

Ejemplares similares